Page last updated: 2024-11-05

thalidomide and Laryngeal Diseases

thalidomide has been researched along with Laryngeal Diseases in 3 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Laryngeal Diseases: Pathological processes involving any part of the LARYNX which coordinates many functions such as voice production, breathing, swallowing, and coughing.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Wei, C1
Zhou, DB1
Duong, DJ1
Moxley, RT1
Kellman, RM1
Pincus, SH1
Gaspari, AA1
Strauss, RM1
Bäte, J1
Nischal, KK1
Clayton, T1
Gooi, J1
Darling, JC1
Newton-Bishop, JA1

Other Studies

3 other studies available for thalidomide and Laryngeal Diseases

ArticleYear
Long-time remission of laryngeal Rosai-Dorfman disease with thalidomide: a report of three cases.
    Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1

    Topics: Adult; Female; Histiocytosis, Sinus; Humans; Laryngeal Diseases; Larynx; Male; Remission Induction;

2021
Thalidomide therapy for cicatricial pemphigoid.
    Journal of the American Academy of Dermatology, 2002, Volume: 47, Issue:2 Suppl

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dapsone; Dermatologic Agents; Humans; Immunosuppressi

2002
A child with laryngo-onychocutaneous syndrome partially responsive to treatment with thalidomide.
    The British journal of dermatology, 2006, Volume: 155, Issue:6

    Topics: Adolescent; Conjunctival Diseases; Epidermolysis Bullosa; Female; Humans; Immunosuppressive Agents;

2006